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The NLR family of proteins is recognized for its roles in inflamma-
some-mediated responses to both pathogen-associated molecular pat-
terns and damage-associated molecular patterns1. However, several 
NLR proteins, including NLRX1, NLRC3, NLRC5 and NLRP12, act 
as negative regulators of innate immunity with the ability to check 
type I interferon responses or NF- B-induced pro-inflammatory 
cytokines2–5. NLRX1 is distinguished from other members of the NLR 
family by its localization to mitochondria, where it interacts with 
MAVS through its unique amino-terminal X domain and nucleotide-
binding–oligomerization domain, sequesters MAVS and suppresses 
virus-induced interferon responses mediated by the pathogen sensor 
RIG-I6. NLRX1 also negatively regulates lipopolysaccharide-induced 
activation of NF- B, interacting with the adaptor TRAF6 in unstimu-
lated cells and being recruited to the NEMO–IKK signaling complex 
following lipopolysaccharide stimulation via its leucine-rich-repeat 
domain3. Deletion or functional knockdown of NLRX1 results in 
heightened interferon responses to the synthetic RNA duplex and 
Toll-like receptor 3 (TLR3) agonist poly(I:C) or RNA viruses, as well 
as increased inflammatory responses3,6,7. Acting like a Swiss Army 
knife, NLRX1 also interacts with STING through its nucleotide-
binding–oligomerization domain and thereby inhibits interferon 
responses to DNA viruses mediated through the cGAS–cGAMP sig-
naling pathway8. Abundant evidence thus supports the concept that 
NLRX1 functions as a checkpoint inhibitor of early innate immune 
responses to both DNA viruses and RNA viruses.
However, not all studies have shown that NLRX1 exerts negative 
regulatory effects on innate immune responses to viruses. Sendai 
virus (SeV)-induced RIG-I- and MAVS-dependent phosphorylation 
of IRF3 and production of interferon-  (IFN- ) and the chemok-
ine IP10 (CXCL10) are reported to be unchanged in Nlrx1−/− mouse 
embryonic fibroblasts (MEFs), relative to that of wild-type MEFs, as 
are cytokine IL-6 and IFN-  responses to poly(I:C)9. Although inflam-
matory responses to infection with influenza virus are enhanced in 
the lungs of Nlrx1−/− mice relative to those in the lungs of of wild-type 
mice7, their macrophage-mediated interferon responses are impaired, 
secondary to enhanced apoptosis10. Also, rather than inhibiting NF-
B signaling, overexpression of NLRX1 enhances such signaling by 
amplifying the production of reactive oxygen species in response to 
several stimuli11. Such findings are puzzling given that the preponder-
ance of evidence favors a negative regulatory role for NLRX1. While 
they might reflect different experimental conditions, they have fueled 
controversy about the regulatory role of NLRX1.
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NLRX1 promotes immediate IRF1-directed antiviral 
responses by limiting dsRNA-activated translational 
inhibition mediated by PKR
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NLRX1 is unique among the nucleotide-binding-domain and leucine-rich-repeat (NLR) proteins in its mitochondrial localization 
and ability to negatively regulate antiviral innate immunity dependent on the adaptors MAVS and STING. However, some 
studies have suggested a positive regulatory role for NLRX1 in inducing antiviral responses. We found that NLRX1 exerted 
opposing regulatory effects on viral activation of the transcription factors IRF1 and IRF3, which might potentially explain such 
contradictory results. Whereas NLRX1 suppressed MAVS-mediated activation of IRF3, it conversely facilitated virus-induced 
increases in IRF1 expression and thereby enhanced control of viral infection. NLRX1 had a minimal effect on the transcription 
of IRF1 mediated by the transcription factor NF- B and regulated the abundance of IRF1 post-transcriptionally by preventing 
translational shutdown mediated by the double-stranded RNA (dsRNA)-activated kinase PKR and thereby allowed virus-induced 
increases in the abundance of IRF1 protein.
Here we sought to understand how NLRX1 influences innate 
immune responses to viral infection of human hepatocytes. 
Hepatocytes are targeted for infection by several medically impor-
tant viruses, including hepatitis A virus (HAV) and hepatitis C virus 
(HCV), which are RNA viruses that cause inflammatory diseases of 
the liver12. We found that NLRX1 competed with dsRNA-activated 
PKR for binding to viral RNA and that it promoted early innate 
immune antiviral responses by protecting NF- B-driven increases 
in the expression of IRF1 from translational suppression mediated 
by PKR. Hepatocytes deficient in NLRX1 expression had diminished 
accumulation of IRF1 but more formation of IRF3 dimers in response 
to viral infection, relative to that of hepatocytes sufficient in NLRX1; 
this revealed opposing actions of NLRX1 on key signaling pathways. 
Our data identify a previously unknown and sophisticated regulation 
of early innate immune responses by NLRX1 that, overall, promotes 
immediate antiviral defense in hepatocytes.
RESULTS
NLRX1 is a positive immunoregulator in hepatocytes
To determine how NLRX1 influences antiviral responses in hepato-
cytes, we used CRISPR-Cas9 gene editing to eliminate its expression 
in PH5CH8 cells, which are T antigen–transformed primary human 
hepatocytes with functional signaling via RIG-I and TLR3 (refs. 
13,14). NLRX1 expression was detected in PH5CH8 cells transduced 
with a nontargeting single guide RNA (sgRNA) with a scrambled 
sequence (called ‘control PH5CH8 cells’ throughout) but not in either 
of two independent PH5CH8 cell lines (NLRX1-T2 and NLRX1-T3)  
transduced with different NLRX1-specific sgRNAs (Fig. 1a and 
Supplementary Table 1). We initiated HCV replication in these cells 
by electroporating synthetic viral RNA and the duplex microRNA 
miR-122, an essential HCV host factor that PH5CH8 cells lack15, 
together into the cells. We demonstrated that subsequent increases in 
viral RNA were due to true viral replication because they were blocked 
by a direct-acting antiviral inhibitor (Fig. 1b). We also infected the 
cells directly with HAV16. Replication of each virus was enhanced in 
NLRX1-deficient (NLRX1-T2 and NLRX1-T3) cells relative to that of 
control PH5CH8 cells (Fig. 1b). We similarly assessed HAV replica-
tion in primary human fetal hepatoblasts (HFHs). Partial depletion 
of NLRX1 via RNA-mediated interference boosted viral replication 
in cells from two donors (Fig. 1c), which confirmed an antiviral role 
for NLRX1 in human liver cells.
Although innate immune responses restrict infection with HAV 
or HCV in PH5CH8 cells, it is difficult to document the induction 
of antiviral cytokines in these cells following viral challenge. We 
thus employed a classic agonist of RIG-I signaling, SeV, to define the 
effect of NLRX1 deficiency on cytokine responses. We observed sig-
nificantly lower IFNB1, IFNL1, IL1B and IL6 mRNA responses early 
(at 3 h) in SeV-infected NLRX1-deficient (NLRX1-T2 and NLRX1-
T3) cells than in SeV-infected control PH5CH8 cells (Fig. 1d).  
This effect was no longer evident at 8 h, by which time these responses 
had substantially subsided (Supplementary Fig. 1a). NLRX1 defi-
ciency also impaired the accumulation of IL1B and IL6 mRNA, 
but not that of IFNB1 mRNA, in response to poly(I:C) added to 
the medium (Fig. 1e). NLRX1 deficiency consistently reduced the 
amount of IL-6 protein induced in response to stimulation with SeV 
or poly(I:C) (Fig. 1f). Likewise, small interfering RNA (siRNA)-medi-
ated depletion of NLRX1 significantly impaired the increase in IL-6 
protein induced by infection of primary HFHs with SeV (Fig. 1g). 
Neither HAV nor HCV replicates in mouse cells, but we observed a 
reduction of approximate fourfold in the early (3-hour) intrahepatic 
Ifnb and Il6 mRNA responses to synthetic HAV RNA administered  
intravenously to Nlrx1−/− mice, relative to the responses in their wild-
type counterparts (Fig. 1h).
Supplementing PH5CH8 cells with the antioxidant NAC (N-acetyl-
l-cysteine) did not abolish the positive effect of NLRX1 deficiency on 
the replication of an HCV reporter virus, nor did treating cells with 
an inhibitor of endoplasmic reticulum stress (TUDCA) or autophagy  
(3-MA) (Supplementary Fig. 1b). Thus, the increased HCV rep-
lication in NLRX1-deficient cells was probably not due to dimin-
ished production of reactive oxygen species11,17 or to the influence 
of NLRX1 depletion on autophagy or the response to endoplasmic 
reticulum stress18,19.
To ascertain whether the proviral effect of NLRX1 deficiency 
resulted from a reduction in early innate immune response, we 
designed a Transwell assay for soluble antiviral factors (Supplementary 
Fig. 1c). We assessed replication of an HCV reporter virus in indicator 
cells separated by a permeable membrane from NLRX1-deficient cells 
or control PH5CH8 cells, each stimulated by replication-competent 
HCV RNA, and found greater replication of the reporter virus in indi-
cator cells exposed to NLRX1-deficient cells than in those exposed to 
control PH5CH8 cells (Supplementary Fig. 1c). Inhibition of JAK-
STAT signaling with ruxolitinib (an inhibitor of JAK1 and JAK2) 
or tofacitinib (an inhibitor of JAK3) also substantially reduced the 
difference in HCV replication in NLRX1-T3 cells relative to that in 
control PH5CH8 cells (Supplementary Fig. 1d), consistent with the 
suppression of viral replication by cytokine responses involving JAK 
signaling. Depleting cells of NLRX1 had no effect on the replica-
tion of HAV or HCV in RIG-I-deficient Huh-7.5 human hepatoma 
cells20 (Supplementary Fig. 1e) or in MAVS-deficient PH5CH8 cells 
(Supplementary Fig. 1f). Collectively, these results defined NLRX1 as 
a positive regulator of soluble RIG-I- and MAVS-mediated antiviral 
responses in human hepatocytes.
NLRX1 regulates IRF3 and IRF1 responses differentially
We carried out a series of dual-luciferase-promoter assays to deter-
mine if NLRX1 directly regulated the transcription of cytokine-encod-
ing genes. NLRX1 deficiency had little effect on the basal activity 
of the NF- B-responsive promoter PRDII but modestly reduced its 
activation by SeV (Fig. 2a). Consistent with that, overexpression of 
NLRX1 enhanced the activation of PRDII triggered by SeV (Fig. 2a). 
In contrast, NLRX1 deficiency minimally affected activation of the 
IFNB1 promoter and had no effect on the IRF3-responsive promoter 
4*PRD(I/III) (Supplementary Fig. 2a,b). We also assessed the effect 
of NLRX1 deficiency on the stability of IL6 mRNA, as IL-6 expression 
is regulated in part through 3  untranslated region (UTR) sequences 
programmed for rapid mRNA turnover21. NLRX1 deficiency had 
no effect on IL6 mRNA decay in cells treated with actinomycin D 
(Supplementary Fig. 2c), nor did overexpression of NLRX1 alter 
luciferase expression from mRNA transcripts containing the IL6 3  
UTR (Supplementary Fig. 2d). In aggregate, these data suggested 
that NLRX1 had a positive but limited effect on the activation of 
NF- B-responsive promoters by SeV and had no influence on the 
stability of IL6 mRNA.
To more directly investigate the influence of NLRX1 deficiency 
on the activation of NF- B, we assessed SeV-induced signaling 
via the NF- B subunit RELA (p65). NLRX1 deficiency minimally 
affected phosphorylation of the inhibitory cytoplasmic NF- B 
chaperone NFKBIA (I B ) or RELA in SeV-infected PH5CH8 cells 
(Supplementary Fig. 2e). An electrophoretic mobility-shift assay 
with an NF- B probe revealed a significant but quantitatively small 
decrease in the intensity of SeV-induced band shifts in NLRX1- 












































































































































































































































































































































































Figure 1 NLRX1 is a positive regulator of innate immunity and an antiviral factor in hepatocytes. (a) Immunoblot analysis of NLRX1  
and actin (loading control throughout) in control PH5CH8 cells (Control), NLRX1-T2 cells and NLRX1-T3 cells (above lanes). (b) qRT-PCR  
analysis of genomic RNA from HCV (left) and HAV (right) in control PH5CH8 cells, NLRX1-T2 cells and NLRX1-T3 cells (horizontal axis)  
transfected for 24 h with HCV RNA, in the presence (+DAA) or absence (−DAA) of a direct-acting antiviral inhibitor (left) or  
infected for 72 h with HAV (right); result are presented relative to the abundance of viral RNA at 6 h (left) or in control PH5CH8 cells at 24 h (right). 
(c) qRT-PCR analysis (top) of HAV genomic RNA in primary HFHs (from two different donors; horizontal axis) at 72 h after treatment with control
siRNA (si-Control) or partial depletion of NLXR1 with NLRX1-specific siRNA (si-NLRX1) (key), presented relative to the abundance of viral RNA at
5 h; below, immunoblot analysis of NLRX1 in the cells above. (d,e) qRT-PCR analysis of IFNB1, IFNL1, IL1B and IL6 mRNA in control PH5CH8
cells, NLRX1-T2 cells and NLRX1-T3 cells (key) left uninfected (0) or infected for 3 h with SeV (d) or left untreated (0) or stimulated with poly(I:
C) added to medium for 3 h (e); results were normalized to those of ACTB. (f,g) ELISA of IL-6 in control PH5CH8 cells, NLRX1-T2 cells and NLRX1-
T3 cells (key) infected with SeV as in d or stimulated with poly(I:C) as in e (horizontal axis) (f), and in HFHs treated with siRNA as in c (key) and
mock infected or infected with SeV (horizontal axis) (g). (h) qRT-PCR analysis of Ifnb and Il6 mRNA in the liver of wild-type (WT) and Nlrx1−/− mice
(horizontal axis) 3 h after hydrodynamic injection of HAV RNA; results were normalized to those of Actb. Each symbol (b–h) represents an individual
technical replicate (b–d (IL1B and IL6), e–g), experiment (d, IFNB1 and IFNL1) or mouse (h) (mean + s.e.m in each). NS, not significant
(P > 0.05); *P < 0.05, ** P < 0.01, ***P < 0.001 and ****P < 0.0001, control cells versus cells depleted of NLRX1 (except where indicated
otherwise) (two-way analysis of variance (ANOVA) (b (left), d–f) or t test (b (right), c,g,h)). Data are representative of three experiments (a), three
independent experiments with n = 2 (left) or n = 3 (right) technical replicates (b), two experiments with n = 3 (donor 1) or n = 4 (donor 2) technical
replicates (c), three experiments with n = 3 technical replicates in each (d (IL1B and IL6), e), three experiments (f) or two experiments with two
donors (g), with n = 3 technical replicates in each (f,g) or one experiment with n = 3 mice per genotype (h) or are from two independent experiments
with n = 4 technical replicates (d, IFNB1 and IFNL1).
in control PH5CH8 cells (Fig. 2b). We concluded from these data 
that NLRX1 deficiency minimally suppressed SeV-induced NF- B 
signaling in PH5CH8 cells and that this subtle impairment of NF- B 
signaling probably did not explain the marked reductions we observed 
in cytokine expression.
To further test our hypothesis, we assessed how depleting RELA 
influenced IL-6 production after SeV infection and the modula-
tion of IL-6 expression by NLRX1 in PH5CH8 cells. As anticipated, 
RELA deficiency caused a large decrease in the SeV-induced expres-
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Figure 2 Effect of NLRX1 deficiency on NF- B signaling and the activation of IRF1 and IRF3 in SeV-infected PH5CH8 cells. (a) Activity of a (firefly)  
luciferase reporter for the promoter PRDII in control PH5CH8 cells, NLRX1-T2 cells and NLRX1-T3 cells (key) (left) or PH5CH8 cells transfected with 
empty vector (EV) or transfected to overexpress NLRX1 (key) (right), all mock infected or infected with SeV (horizontal axis); results are presented 
relative to renilla luciferase activity. (b) Electrophoretic mobility-shift assay of NF- B without nuclear extracts (Null) or with nuclear extracts from 
control PH5CH8 cells, NLRX1-T2 cells and NLRX1-T3 cells (above lanes) mock infected or infected with SeV (below blot) (top left), together with 
immunoblot analysis of lamin A/C as a loading control (bottom left), and mean infrared fluorescence intensity of the shifted probe (assessed as at 
left), presented relative to that in SeV-infected control PH5CH8 cells (right). ND, not detected. (c) Immunoblot analysis of NLRX1, RELA and GAPDH 
(loading control throughout) in NLRX1- and RELA-sufficient PH5CH8 cells (Control), RELA-deficient PH5CH8 cells (RELA-KO-3, NLRX1-KO −) and 
PH5CH8 cells doubly deficient in NLRX1 and RELA (RELA-KO-3, NLRX1-KO T3) (above lanes) (left), and ELISA of IL-6 in cells as at left (key), left 
uninfected (0) or infected for 3 h with SeV (horizontal axis) (right). (d,e) Immunoblot analysis (left) of IRF3 monomers and dimers (right margin)  
(d) and of NLRX1 and IRF1 (left margin) (e) in control PH5CH8 cells, NLRX1-T2 cells and NLRX1-T3 cells (above lanes) mock infected or infected with
SeV (below blots); right, quantification of the intensity of IRF3 dimers (d) or IRF1 (e), relative to that of GAPDH. (f) Immunoblot analysis of NLRX1 (far
left) or IRF3 and IRF1 (middle left) in NLRX1-T3 cells transfected with empty lentivirus vector (EV) or with lentivirus vector encoding NLRX1 (above
lanes) and left uninfected (far left) or mock infected or infected with SeV (below blots) (middle left); right, quantification of the intensity of IRF3
dimers (middle right) or IRF1 (far right), relative to that of GAPDH. Each symbol represents an individual technical replicate (a,c) or experiment (b,d–f)
(mean + s.e.m. throughout). *P < 0.05, **P < 0.01,***P < 0.001 and ****P < 0.0001, control cells versus cells depleted of NLRX1 (two-way ANOVA
(a,e) and t test (b–d,f)). Data are representative of three independent experiments with n = 3 technical replicates (a), four (b,d), three (e) or two (f)
independent experiments (b,d–f), or two independent experiments with n = 3 technical replicates in each (c).
expression resulted in a further reduction in IL-6 production in 
RELA-deficient cells (Fig. 2c). Thus, the negative effect of NLRX1 
deficiency on the IL-6 response that we observed in RELA-replete 
cells was preserved in RELA-deficient cells. Collectively, these results 
indicated that NLRX1 regulated IL-6 production downstream and 
independently of NF- B.
Although our data showed that IL-6 was strongly regulated by NF-
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Figure 3 NLRX1–IRF1 signaling dominates the antiviral cytokine response in hepatocytes. (a,b) ELISA of IL-6 (middle) and qRT-PCR analysis of HAV 
genomic RNA (right) in IRF3-deficient PH5CH8 cells (IRF3-KO) and PH5CH8 cells doubly deficient in IRF3 and NLRX1 (IRF3-KO + T3) (a), or in 
IRF1-deficient PH5CH8 cells (IRF1-KO) and PH5CH8 cells doubly deficient in IRF1 and NLRX1 (IRF1-KO + T3) (b), mock infected or infected for  
3 h with SeV (a,b, middle) or for 72 h with HAV (a, right) or infected for 48 or 72 h with HAV (b, right) (horizontal axes), and immunoblot analysis (left) 
of NLRX1 and IRF1 (a) or of NLRX1 and IRF3 dimers (b) in cells as at right, left uninfected (0) or infected for 3 h with SeV (above lanes) (immunoblot 
analysis of IRF1-deficient and IRF3-deficient cells, Supplementary Fig. 2f); qRT-PCR results are presented relative to those of cells at 4 h.  
(c) Immunoblot analysis of NLRX1 and IRF1 in HFHs treated with control siRNA or partially depleted of NLRX1 via NLRX1-specific siRNA (above
lanes) (top) or treated with siRNA as above and left uninfected (0) or infected for 3 h with SeV (below blot) (middle), and quantification of IRF1
(infrared fluorescence intensity) in immunoblot analysis as above, relative to that of GAPDH. (d,e) qRT-PCR analysis of Ifnb, Il6 and Tnf mRNA (d),
immunoblot analysis of NLRX1 and IRF1 (e, left) and quantification of IRF1 as in c (e, right) in wild-type and Nlrx1−/− BMDMs (top) or MEFs (bottom)
left uninfected (0) or infected for 3 h (d) or 1–6 h (e) with SeV. Each symbol (a–d) represents an individual technical replicate (a,b,d) or donor (c) (mean
+ s.e.m in each). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 (t-test). Data are representative of two to three independent experiments
with n = 3 technical replicates in each (a,b), two experiments with two donors (c) or four (BMDM) or two (MEF) independent experiments with n = 3
technical replicates in each (d), or are representative of two independent experiments (e).
either of two members of the IRF family of transcription factors, 
IRF1 and IRF3, suppressed early (3-hour) IL1B and IL6 mRNA and 
IL-6 protein responses to SeV (Supplementary Fig. 2f–h). Because 
IRF1 and IRF3 regulate the induction of IFNB1 and IFNL1 tran-
scripts in human hepatoma cells22, we assessed the effect of NLRX1 
deficiency on IRF3 and IRF1 responses in PH5CH8 cells. IRF3 is 
constitutively expressed and is activated by phosphorylation, which 
leads to its dimerization and cytoplasmic–nuclear translocation23. 
NLRX1 deficiency significantly enhanced this response and led to an 
increase in the SeV-induced formation of IRF3 dimers (Fig. 2d). Basal 
expression of IRF1 protein was low in mock-infected cells but was  
substantially induced by infection with SeV (Fig. 2e). In contrast 
to the enhancement observed in the activation of IRF3, NLRX1 
deficiency significantly reduced the SeV-triggered increases in the 
abundance of IRF1 (Fig. 2e). Reconstituting NLRX1 expression in 
NLRX1-T3 cells with recombinant lentivirus reversed both of those 
changes (Fig. 2f). Collectively, these data revealed that NLRX1  
regulated SeV-induced IRF3 signaling and IRF1 signaling in hepato-
cytes differentially, suppressing the activation of IRF3 but enhancing 
increases in IRF1 expression.
NLRX1’s promotion of IRF1 dominates in hepatocytes
Because NLRX1 deficiency suppresses innate immunological con-
trol of viral replication in hepatocytes, we reasoned that the positive 
regulation of IRF1 by NLRX1, rather than its negative regulation of 
IRF3, probably dominates cytokine responses in hepatocytes. To test 
our hypothesis, we depleted IRF1- and IRF3-deficient PH5CH8 cells 
of NLRX1 expression and assessed responses to SeV challenge in the 
resulting NLRX1–IRF3 or NLRX1–IRF1 doubly deficient cells. In 
IRF3-deficient cells, the IRF1 and IL-6 protein responses to infec-
tion with SeV were suppressed and HAV replication was enhanced by 
depletion of NLRX1 (Fig. 3a). Thus, the effect of NLRX1 depletion 
in IRF3-deficient PH5CH8 cells was similar to that in unmodified 
PH5CH8 cells. In contrast, depleting IRF1-deficient cells of NLRX1 
enhanced the formation of IRF3 dimers (as in IRF1-replete cells) but 
enhanced the SeV-induced production of IL-6 and also suppressed 
HAV replication (Fig. 3b). Thus, the effects of NLRX1 depletion on 
cytokine expression and viral replication were reversed in IRF1-
deficient cells, which suggested that the NLRX1–IRF1 signaling axis 
is dominant in hepatocytes. Consistent with that conclusion, the 
reduced production of IL-6 in SeV-infected HFHs depleted of NLRX1  
(Fig. 1g) was accompanied by a reduction in the accumulation of 
IRF1 protein (Fig. 3c).
Most reports suggest that rather than enhancing such responses, 
NLRX1 suppresses, early innate immune responses in bone-mar-
row-derived macrophages (BMDMs) and primary MEFs6–8. Thus,  
we sought to determine whether IRF1 signaling was negatively or 
positively regulated by NLRX1 in these cell types. Consistent with a 
suppressive effect on innate immunity, we found that loss of NLRX1 
enhanced the SeV-mediated Ifnb, Tnf and Il6 mRNA responses in 
mouse BMDMs and MEFs (Fig. 3d). Despite that, NLRX1 deficiency 
reduced the SeV-triggered increase in the abundance of IRF1 protein 
in both cell types (Fig. 3e). Thus, the positive regulation of IRF1 
signaling by NLRX1 was not specific to hepatocytes or human cells. 
The finding that cytokine responses were enhanced, while IRF1 
induction was decreased, in BMDMs and MEFs depleted of NLRX1 
indicated that IRF1 did not have a dominant role in determining 
cytokine responses in these cells. Thus, the ultimate effect of NLRX1 
on early antiviral responses was determined by whether IRF1 or IRF3 
dominated in driving the response.
NLRX1 enhances IRF1 protein synthesis in infected cells
IRF1 is the ‘founding member’ of the IRF family, and its expression 
is induced rapidly by viral infection24,25. However, the mechanisms 
that mediate this response are poorly understood. Given its role in 
initiating IRF3-directed responses to SeV in hepatocytes20, we rea-
soned that RIG-I and its adaptor MAVS might mediate the IRF1 
response. Consistent with that, depleting cells of MAVS significantly 
suppressed both IRF3 responses and IRF1 responses to SeV infection 
in PH5CH8 cells (Supplementary Fig. 3a). The loss of SeV-induced 
dimerization of IRF3 and expression of IRF1 protein was not reversed 
by additional depletion of NLRX1 in MAVS-deficient PH5CH8 cells 
(Supplementary Fig. 3a).
Consistent with published studies showing that increased IRF1 
transcription drives the IRF1 protein response to viral infection25, 
globally inhibiting transcription with actinomycin D completely abol-
ished the IRF1 protein response to SeV (Supplementary Fig. 3b). To 
better understand how NLRX1 might regulate this IRF1 response, we 
assessed the roles of IRF3 and NF- B. Notably, depleting cells of IRF3 
had no effect on either the transcription of IRF1 or the expression of 
IRF1 protein (Supplementary Fig. 3c). In contrast, depleting cells of 
RELA significantly suppressed both the transcription of IRF1 and the 
increase in expression of IRF1 protein in response to SeV in PH5CH8 
cells (Supplementary Fig. 3d). siRNA-mediated silencing of NFKB1, 
which encodes the NF- B subunit p50, modestly diminished the IRF1 
protein response to SeV infection, and in combination with RELA 
deficiency, it substantially reduced the SeV-induced abundance of 
IRF1 transcripts (Supplementary Fig. 3e,f). Collectively, these data 
demonstrated that the immediate (3-hour) increase in the expres-
sion of IRF1 protein in response to infection with SeV was driven by 
signaling via MAVS and NF- B in PH5CH8 cells.
Notably, although NLRX1 deficiency modestly enhanced the  
SeV-induced abundance of IRF3 transcripts (Supplementary Fig. 4a), 
it had no effect on either the abundance of IRF1 transcripts (Fig. 4a) 
or the stability of IRF1 mRNA (Fig. 4b). These data were in agreement 
with our earlier observations indicating an only modest impairment 
of NF- B signaling in NLRX1-deficient cells (Fig. 2b) and collectively 
indicated that NLRX1 regulated IRF1 expression post-transcrip-
tionally. To gain insight into whether this negative regulation of the 
IRF1 response was due to enhanced degradation of IRF1 or reduced 
synthesis of IRF1 protein, we globally inhibited protein synthesis 
in SeV-infected cells with cycloheximide and monitored the subse-
quent decay of IRF1 protein. Despite the greater initial abundance of 
IRF1 in control PH5CH8 cells than in NLRX1-T3 cells, the half-life  
(stability) of IRF1 protein in NLRX1-T3 cells was indistinguishable 
from that in control PH5CH8 cells (Fig. 4c and Supplementary 
Fig. 4b). Collectively, these data suggested that the reduced abundance 
of IRF1 protein in NLRX1-deficient cells resulted from impaired 
translation of IRF1 mRNA. Consistent with that, globally blocking 
protein synthesis with puromycin completely abolished the effect 
of NLRX1 deficiency on the IRF1 response to infection with SeV 
(Supplementary Fig. 4c).
To determine how NLRX1 might influence protein synthesis, we 
measured the incorporation of [35S]-labeled methionine and cysteine 
([35S]-Met-Cys) into protein. Protein synthesis in NLRX1-T3 cells 
was qualitatively similar to that in control PH5CH8 cells, both before 
infection with SeV and after such infection (Supplementary Fig. 4d). 
However, whereas infection with SeV induced a significant, quantita-
tive increase in protein synthesis in control PH5CH8 cells, it had a much 
smaller, nonsignificant effect on NLRX1-T3 cells (Fig. 4d). The absence 
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Figure 4 NLRX1 facilitates immediate IRF1 antiviral responses by promoting global protein synthesis in SeV-infected cells. (a) qRT-PCR analysis of 
IRF1 mRNA in control PH5CH8 cells, NLRX1-T2 cells and NLRX1-T3 cells (key) left uninfected (0) or infected for 3 h with SeV (horizontal axis); 
results were normalized to those of ACTB. (b) Stability of IRF1 mRNA in SeV-infected control PH5CH8 cells and NLRX1-T3 cells (key), assessed as 
IRF1 mRNA remaining at various times (horizontal axis) after treatment with actinomycin D (Act D). (c) Stability of IRF1 protein in SeV-infected control 
PH5CH8 cells and NLRX1-T3 cells (key), assessed by quantification of band intensity (immunoblot analysis, Supplementary Fig. 4b) at various times 
(horizontal axis) after treatment with cycloheximide (CHX). (d) Nascent protein synthesis in control PH5CH8 cells and NLRX1-T3 cells (key) mock 
infected (0) or infected for 3 h with SeV, assessed as the incorporation of [35S]-Met-Cys into cellular proteins (precipitated from cells by trichloroacetic 
acid), relative to that in uninfected control PH5CH8 cells, set as 100% (immunoblot analysis, Supplementary Fig. 4d). (e) Confocal microscopy (left) 
of control PH5CH8 cells and NLRX1-T3 cells mock infected (0) or infected for 3 h with SeV (left margin) and pulse-labeled with puromycin, assessing 
global protein synthesis by staining of puromycin with specific antibody, with nuclei counterstained with the DNA-binding dye DAPI (below images), 
and frequency of cells with puromycin labeling exceeding an arbitrary threshold (far right). Scale bar (left), 40 m. (f) Polysome profile of IRF1, IRF3 
or ACTB mRNA (key) in mock- or SeV-infected (left margin) control PH5CH8 cells and NLRX1-T3 cells (above plots), plotted as absorbance at 254 nm 
(A254) (left vertical axis) and qRT-PCR analysis of mRNA (presented as percent of total mRNA in each fraction; right vertical axis); red vertical lines 
distinguish polysome-associated mRNA (fractions 7–14) from non–polysome-associated mRNA (fractions 1–6). (g) Proportion of IRF1, IRF3 or ACTB 
mRNA (horizontal axis) associated with translationally active polysomes (fractions 7–14 in f) in control PH5CH8 cells and NLRX1-T3 cells (above 
plot) mock infected or infected with SeV (key). (h) Ratio of 80S to 40S in mock- or SeV infected (horizontal axis) control PH5CH8 cells and NLRX1-T3 
cells (key), calculated from the area under the curve of 40S and 80S peaks of A254 traces. Each symbol (a,d,e,g,h) represents an individual technical 
replicate (a) or experiment (d,e,g,h); small horizontal lines (d,e) indicate the mean (  s.e.m.). *P < 0.05, **P < 0.01 and ***P < 0.001 (two-way 
ANOVA (a,d,e,g) or t-test (h)). Data are representative of three experiments with n = 3 technical replicates in each (a; mean + s.e.m.), two experiments 
with n = 3 technical replicates (b; mean  s.e.m.), six experiments (c; mean  s.e.m.), three experiments with n = 1-3 technical replicates (d), three 
experiments (e, left), three experiments with an average of 176 cells per condition (e, right), or two to three experiments (f–h; mean + s.e.m. in g,h).
present in the lysates of uninfected cells (Supplementary Fig. 4d) 
indicated that this increase was due to enhanced cellular protein 
synthesis, not viral protein synthesis. As an independent meas-
ure of protein synthesis, we pulse-labeled NLRX1-T3 cells with a 
low concentration of puromycin and used confocal microscopy to 
monitor its incorporation into nascent protein at a single-cell level 
(Fig. 4e). Infection with SeV induced an increase in nascent protein 
synthesis in a large proportion of control PH5CH8 cells but not in 
NLRX1-T3 cells (Fig. 4e). We obtained similar results with NLRX1-
T2 cells, at both a whole-cell-culture level and a single-cell level of 
analysis (Supplementary Fig. 4e), which excluded the possibility that 















































































































































































































































































































Figure 5 NLRX1 reduces the activation of PKR and subsequent inhibition of protein synthesis by competing for binding to viral RNA. (a) Immunoblot 
analysis of total NLRX1 and IRF1 and phosphorylated (p-) PKR and eIF2  (left margin) in control PH5CH8 cells and NLRX1-T3 cells (above lanes) 
mock infected or at 4.5 h after infection with SeV (below blots), assessing PKR–eIF2  signaling (left), and quantification (infrared fluorescence 
intensity) of phosphorylated PKR or eIF2 , normalized to that of actin (right). (b) Immunoblot analysis of PKR and NLRX1 in control PH5CH8 cells (far 
left) or PKR-deficient PH5CH8 cells (PKR-KO-1 or PKR-KO-3 (above lanes); middle) or PH5CH8 cells deficient in both NLRX1 and PKR (PKR-KO-1 or 
PKR-KO-3 (above lanes) plus NLRX1-T3 (below blot); right). (c) Immunoblot analysis of IRF1 (top) and IRF3 dimers (middle) in control PH5CH8 cells 
(Ctrl) and NLRX1-T3 cells (T3) (left blots) or PKR-deficient PH5CH8 cells (PKR-KO-1 or PKR-KO-3 (above blots) and – (above lanes); right) or PH5CH8 
cells deficient in both NLRX1 and PKR (PKR-KO-1 or PKR-KO-3 (above blots) and T3 (above lanes); right). (d,e) ELISA of IL-6 (d) and qRT-PCR 
analysis of HAV RNA (e) in cells as in c (below plots); qRT-PCR results are presented relative to those of control PH5CH8 cells, set as 1.  
(f) Global protein synthesis in PKR-deficient PH5CH8 cells (PKR-KO-1) and PH5CH8 cells deficient in both NLRX1 and PKR (PKR-KO-1 + T3) (key)
mock infected (0) or infected for 3 h with SeV (horizontal axis), assessed as incorporation of [35S]-Met-Cys (as in Fig. 4d). (g) qRT-PCR analysis of HAV
RNA (top left) and immunoblot analysis of NLRX1 (bottom left) in control PH5CH8 cells and NLRX1-T3 cells (key) transfected for 3 h with HAV RNA,
assessed as input samples or after immunoprecipitation (IP) with antibody to NLRX1 (horizontal axis or above lanes). Right, immunoblot analysis of
NLRX1 precipitated together with biotin-tagged HAV RNA (HAV RNA–NLRX1; right margin) in lysates of control PH5CH8 cells or NLRX1-T3 cells (left
half) or NLRX1-T3 cells (below blot) transfected with empty vector or vector expressing NLRX1 (above lanes; right half); left margin (◊), endogenous
NLRX1 associated with HAV RNA, with high or low detection intensity. (h) Immunoblot analysis (left) of NLRX1 and PKR in lysates of NLRX1-T3 cells
supplemented with various doses (above lanes) of purified recombinant NLRX1 and with biotin-tagged HAV RNA (top) or poly(I:C) (bottom); right,
quantification of the binding of HAV RNA (near right) or poly(I:C) (far right) to PKR. Each symbol (a,d,e,f,g,h) represents an individual experiment
(a,f,g,h) or technical replicate (d,e) (mean + s.e.m in each). *P < 0.05, **P < 0.01 and ***P < 0.001 (two-way ANOVA (a,d,f,g) or one-way ANOVA
(e,h)). Data are representative of four independent experiments (a), two independent experiments (b,c), two experiments with n = 3 technical replicates
in each (d,e), two experiments with n = 2 technical replicates (f), two experiments with n = 2–3 technical replicates (g) or three (HAV RNA) or five
(poly(I:C)) experiments (h).
NLRX1-T3 cells. siRNA-mediated depletion of NLRX1 expression 
in primary HFHs also substantially suppressed the SeV-induced 
increases in nascent protein synthesis (Supplementary Fig. 4f).
Although NLRX1 exerted distinctly different regulatory effects 
on SeV-induced cytokine expression in MEFs relative to that human 
hepatocytes, depleting cells of NLRX1 expression reduced the 
SeV-induced increase in the abundance of IRF1 in both cell types 
(Figs. 2e and 3e). Consistent with that finding, the incorporation of 
puromycin into nascent protein was also significantly lower in SeV-
infected MEFs from Nlrx1−/− mice than in those from wild-type mice 
(Supplementary Fig. 4g). Thus, the negative effect of NLRX1 defi-
ciency on protein synthesis in virus-infected cells was not limited to 
human hepatocytes.
To directly characterize the effect of NLRX1 deficiency on the 
translation of mRNA by ribosomes, we used sucrose-density-gradient 
fractionation to profile polysome formation following the infection 
of NLRX1-T3 cells or control PH5CH8 cells with SeV (Fig. 4f). The 
deletion of NLRX1 resulted in a significant shift in the gradient distri-
bution of IRF1, IRF3 and ACTB mRNA from SeV-infected cells, with 
a significantly lower proportion of each mRNA associated with trans-
lationally active polysomes (fractions 7–13) (Fig. 4g). Moreover, the 
formation of translationally competent 80S ribosomes was lower in 
SeV-infected NLRX1-T3 cells than in SeV-infected control PH5CH8 
cells, as shown by the much lower ratio of 80S to the 40S subunit in 
SeV-infected NLRX1-T3 cells than in SeV-infected control PH5CH8 
cells (Fig. 4h and Supplementary Fig. 4h); this suggested a defect in 
initiation of translation. Collectively, these three separate measures 
of protein synthesis—incorporation of [35S]-Met-Cys, puromycin 
labeling and polysome profiling—indicated that the translation of 
mRNA was globally suppressed by the absence of NLRX1 expression 
in SeV-infected cells.
NLRX1 limits PKR-mediated global translational shutdown
The dsRNA-activated kinase PKR is triggered by viral infection to 
phosphorylate the translation-initiation factor eIF2  and thereby 
globally shuts down host-cell translation26. To ascertain whether 
NLRX1 influences that PKR response, we characterized the activation 
of PKR in NLRX1-deficient cells. NLRX1 deficiency enhanced the 
SeV-induced autophosphorylation of PKR, as well as phosphoryla-
tion of the PKR substrate eIF2  (Fig. 5a and Supplementary Fig. 5a).  
To determine whether NLRX1 facilitated virus-induced increases 
in IRF1 protein synthesis by suppressing PKR responses, we gener-
ated PH5CH8 cells doubly deficient in NLRX1 and PKR (Fig. 5b).  
The negative effect of the deletion of NLRX1 on SeV-triggered IRF1 
responses was completely abolished by PKR deficiency (Fig. 5c). PKR 
deficiency also fully restored the SeV-triggered immediate IL-6 pro-
tein response (Fig. 5d) and abolished the beneficial effect conferred 
on HAV replication by NLRX1 deficiency (Fig. 5e). We also assessed 
the effect of SeV infection on nascent protein synthesis in the cells 
doubly deficient in NLRX1 and PKR. In contrast to the lack of increase 
in the incorporation of [35S]-Met-Cys or puromycin into NLRX1-
deficient cells, relative to that in control PH5CH8 cells (Fig. 4d,e),  
protein synthesis increased over time in response to SeV infection in 
both cells doubly deficient in NLRX1 and PKR and those deficient in 
PKR alone (Fig. 5f and Supplementary Fig. 5b).
To explore the mechanism by which NLRX1 suppressed PKR 
responses, we investigated whether NLRX1 physically interacted with 
PKR in hepatocytes. However, no co-immunoprecipitation of PKR 
protein with either endogenous NLRX1 or overexpressed NLRX1 
was detectable in PH5CH8 cells (Supplementary Fig. 5c,d). Since 
NLRX1 binds both viral RNA and poly(I:C), a common surrogate 
for viral dsRNA27,28, we reasoned that NLRX1 might suppress the 
activation of PKR by competing for viral RNA in infected cells. To test 
our hypothesis, we first confirmed that NLRX1 bound HAV genomic 
RNA, which is known to have extensive secondary structure29, in 
bidirectional precipitation assays (Fig. 5g). Next, we designed a cell-
free competition assay in which lysates of NLRX1-deficient cells were 
used as a source of PKR, supplemented with purified recombinant 
NLRX1 protein and biotin-tagged HAV RNA or poly(I:C). The addi-
tion of increasing amounts of recombinant NLRX1 protein led to a 
progressive reduction in the binding of PKR to viral RNA or poly(I:C) 
(Fig. 5h), which indicated that NLRX1 competed with PKR for bind-
ing to viral RNA. Together these results demonstrated that NLRX1 
suppressed the activation of PKR, in part by competitively binding 
viral RNA, and thereby prevented the PKR-mediated translational 
shutdown that would otherwise attenuate IRF1-mediated antiviral 
responses (Supplementary Fig. 5e).
DISCUSSION
Although some studies have reported NLRX1 to be a negative regu-
lator of innate immunity3,6,8,30, others have not confirmed that9,31 
or have even suggested that NLRX1 enhances antiviral responses10. 
Consistent with the latter notion, we found NLRX1 to be an antiviral 
factor and a positive regulator of early innate immune responses in 
human hepatocytes. HAV and HCV, both common causes of viral 
hepatitis in humans, are unrelated, positive-strand hepatotropic RNA 
viruses that share many similarities in their replication cycles and in 
their interactions with innate immunity12. Both produce dsRNA rep-
lication intermediates that induce signaling via RIG-I and TLR3 and 
thereby activate NF- B and members of the IRF family, which leads to 
antiviral defense12,32. To counter those host defenses, both HAV and 
HCV express proteases that target for degradation MAVS and TRIF, 
key adaptors in the RIG-I and TLR3 signaling pathways33–36. Adding 
to those similarities, we found here that NLRX1 acted to restrict the 
replication of both HAV and HCV.
Surprisingly, we observed that NLRX1 had distinct, opposing 
effects on the SeV-induced activation of two members of the IRF 
family. NLXR1 was required for maximal increases in the abundance 
of IRF1 but suppressed the dimerization of IRF3. As key factors in 
inducing cytokine transcription, members of the IRF family are trig-
gered by various stimuli in all cell types. Whereas IRF3 and IRF7 are 
activated by viral infection in most cell types37,38, other family mem-
bers, including IRF1, as well as IRF5, IRF8 and IRF9, are selectively 
activated by different stimuli in a cell-type-dependent manner39–44. 
This complexity in IRF activation provides the diversity of responses 
required for effective host defense. However, it also allows a single 
regulatory molecule, such as NLRX1, to have different functional 
consequences when expressed in different cell types or pathogen con-
texts or, potentially, at different points of time in the response to an 
invading virus. The opposing regulatory activities of NLRX1 on early 
IRF3 and IRF1 responses might account for much of the controversy 
surrounding this protein7,8,10. We found that NLRX1 positively regu-
lated IRF1 signaling in both BMDMs and primary MEFs. However, 
NLRX1 is known to attenuate innate immunological control of viral 
replication in these cell types6–8. We infer from this that IRF1 does 
not have a dominant role in determining the outcome of infection in 
these cells, at least not under the conditions tested, whereas our data 
showed that it did so in hepatocytes. Thus, whether NLRX1 functions 
as a pro-viral factor or an antiviral factor, or neither9,31, probably 
reflects which IRFs dominate in inducing antiviral responses.
Although published studies have indicated that NLRX1 negatively 
regulates lipopolysaccharide- and TLR4-triggered NF- B signaling 
in macrophages and HEK293T human embryonic kidney cells3,7, we 
found that NLRX1 had a slight, positive effect on RIG-I-mediated 
NF- B signaling in hepatocytes. However, this effect was not critical 
for the promotion of early cytokine responses by NLRX1, as our data 
showed that NLRX1 regulated the IL-6 response downstream of the 
influence of NF- B.
Negative regulation of MAVS-mediated IRF3 responses by NLRX1 
has been described previously6, but how NLRX1 affects IRF1 responses 
has not been studied. We found that depleting cells of NLRX1 did not 
alter SeV-induced transcription of IRF1 mRNA in PH5CH8 cells, but 
it significantly reduced the synthesis of IRF1 protein. Reductions in 
protein synthesis were not specific to IRF1 but instead reflected a 
global shutdown of protein synthesis due to enhanced activation of 
PKR, a phenomenon that would probably have its greatest effect on 
proteins that turn over rapidly, such as IRF1, which has a half-life of 
about 60 min.
Emerging evidence is increasingly linking translational control to 
the regulation of immediate responses of the innate immune system. 
Both IRF7 and IRF8 seem to be controlled via global, regulation of 
translation dependent on the translation-initiation factor eIF4E45–47. 
PKR restricts protein synthesis globally by phosphorylating eIF2  and 
thereby blocking the production of virus48. However, activation of 
PKR also reduces the synthesis of effector proteins encoded by inter-
feron-stimulated genes49 and, as we have shown here, the production 
of IRF1 driven by an early, NF- B-mediated response to SeV. PKR is 
thus a double-edged sword, potentially weakening the cell’s antiviral 
defenses as well as presenting a hurdle to be overcome by the virus. 
The negative effect of the activation of PKR on host defense might be 
particularly important when cells are infected with viruses such as 
HCV that can continue to translate their RNAs despite such activa-
tion49. Our data suggest that NLRX1 moderates the potentially nega-
tive consequences of PKR activation by competing with it for binding 
to viral RNA. This is distinct from how other members of the NLR 
family, including NLRP3, NLRP1 and NLRC4, physically interact with 
PKR to maximize activation of the inflammasome50.
We speculate that the opposing actions of NLRX1 on early IRF1 
and IRF3 antiviral responses might underlie much of the controversy 
surrounding the biological function of this member of the NLR family. 
Loss of NLRX1 expression might result in contradictory effects on out-
come of infections by different viruses in different tissues, depending on 
which IRF protein dominates in driving the antiviral response.
METHODS
Methods, including statements of data availability and any associated 
accession codes and references, are available in the online version of 
the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Reagents and antibodies. Puromycin and blasticidin were from Invitrogen. 
3-methyladenine (3-MA), tauroursodeoxycholic acid (TUDCA), N-acetyl- 
l-cysteine (NAC), ruxolitinib, tofacitinib, cycloheximide and actinomycin-D 
were from Sigma-Aldrich. PSI-7977 (Sofosbuvir) was from Chemscene. Poly(I:C) 
(high molecular weight, InvivoGen) was either added to cell culture super-
natants at a final concentration of 50 g/ml or transfected at a concentration 
of 2 g/ml.
Antibodies used in this study included the following: antibody to NLRX1 
(anti-NLRX1) (1:5,000 dilution; this antibody was described previously6); anti-
IRF1 (1:1,000 dilution; clone D5E4, #8478), anti-phospho-NF- B p65 (anti-
p-RELA; 1:1,000 dilution; clone 93H1, #3033), anti-NF- B p65 (anti-RELA; 
1:1,000 dilution; clone D14E12, #8242), anti-p50 (1:1,000 dilution; clone 
5D10D11, #13681), anti-phospho-I B  (1:500 dilution; clone 14D4, #2859), 
anti-I B  (1:1,000 dilution; clone L35A5, #4814), anti-PKR (1:1,1000 dilution; 
clone D7F7, #12297) and antibody to phosphorylated eIF2  (1:1,000 dilution; 
clone S51, #9721), all from Cell Signaling; anti-IRF3 (1:500 dilution; clone 
FL-425, sc-9082), anti-eIF2  (1:500 dilution; clone FL-315, sc-11386) and 
anti-lamin A/C (1:1,000 dilution; clone N-18, sc-6215), all from Santa Cruz; 
antibody to phosphorylated PKR (1:1,000 dilution; clone E120, ab32036) and 
mouse IgG1 (ab18448), both from Abcam; anti-Cardif (anti-MAVS; 1:2,000 
dilution; clone AT107, #ALX-210-929), from Enzo Life Sciences; anti-actin 
(1:40,000 dilution; clone AC-74, A2228), from Sigma; anti-GAPDH (1:50,000 
dilution; AM4300), from Ambion; and anti-puromycin (1: 20,000 dilution for 
immunoblot and 1:10,000 dilution for immunofluorescence; clone 12D10, 
MABE343), from EMD Millipore. Goat anti-mouse IgG (H+L) cross-adsorbed 
secondary antibody (1:300 dilution; A-11001) was from ThermoFisher. IRDye 
680 or 800 secondary antibodies included #926-32211, #926-32212, #926-
32214, #926-68020 and #926-68073 (1:12,000) from LI-COR Biosciences.
Cells. Tissues for preparation of fetal human liver cells were from anonymous 
donors and were provided by the accredited nonprofit corporation Advanced 
Biosciences Resources (ABR); they were obtained from fetuses between 19 weeks 
and 21 weeks of gestation during elective termination of pregnancy. Tissues were 
collected with written informed consent from all donors and in accordance with 
the US Food and Drug Administration CFR Part 1271 Good Tissue Practices 
regulations. Tissue processing and hepatoblast isolation and culture were as 
previously described51. The use of commercially procured fetal liver cells was 
reviewed by the University of North Carolina at Chapel Hill Office of Human 
Research Ethics and was determined to be exempt from review by the University 
of North Carolina at Chapel Hill Institutional Review Board.
293FT cells and human hepatocyte-derived cell lines, including Huh-7.5 
cells52 and PH5CH8 cells13, were mycoplasma free and were cultured as previ-
ously described51. Mouse bone-marrow-derived macrophages (BMDMs) and 
mouse embryo fibroblasts (MEFs) were generated and cultured as previously 
described8.
Mice and HAV RNA inoculation. Age- and sex-matched wild-type and 
Nlrx1−/− mice were previously described7. Animals were stratified by sex 
before randomization. Experiments were performed in a non-blinded fashion 
in accordance with the NIH Guide for the Care and Use of Laboratory Animals 
and with the approval of the Institutional Animal Care and Use Committee 
of the University of North Carolina at Chapel Hill. 13-week-old mice were 
inoculated intravenously with PBS or 15 g in vitro–transcribed HAV RNA 
in a volume of PBS equivalent to ~5% body weight. Mice were killed 3 h 
after injection, and liver tissue was collected for analysis of cytokine-encoding 
mRNA by qRT-PCR.
Virus. Sendai virus (SeV, Cantell strain) was obtained from Charles River 
Laboratory. Cultures were exposed to SeV at a concentration of 600 HA units/
ml. High-titer HAV stock (HM175/18f strain53) was prepared as described
previously54. HAV infection was carried out at a multiplicity of infection
of 10 for PH5CH8 cells or a multiplicity of infection of 1 for Huh-7.5 cells.
Infectious molecular clones for HCV (pJFH1-QL, containing the cell-culture-
adaptive mutation Q221L in the NS3 helicase)55, a reporter virus expressing
Gaussia princeps luciferase (pJFH1-QL/GLuc)51, and HAV (pT7-18f)56 were 
described previously.
Plasmids and oligonucleotides. Firefly luciferase reporter vectors, including 
pIFNB1-Luc, pIRF3-responsive (4*PRD(I/III))-Luc and pPRDII-Luc, as well 
as the Renilla luciferase control reporter vector pRL-TK, were described previ-
ously57. The IL6 3 UTR construct was provided by B. Glaunsinger (University 
of California, Berkeley) and was sub-cloned to psiCHECK2. Plasmids for over-
expression of NLRX1 and PKR were previously described6. An expression vec-
tor for reconstitution of NLRX1 was generated by removal of the TurboGFP-2A 
region from pLOC-RFP58, producing pLOC GFP, which retains the RFP open 
reading frame (ORF) (empty vector, EV). The RFP ORF was then replaced by 
sequence encoding the NLRX1 ORF to produce pLOC-NLRX1T3, using a 
PCR-based strategy as previously described59. Oligonucleotides used in this 
study are listed in Supplementary Table 2. All constructs were verified by 
DNA sequencing.
In vitro transcription and transfection. In vitro transcription and transfec-
tion of viral RNA was performed as previously described51. For biotin labeling 
of HAV RNA, transcription mixes were supplemented with 1× concentrated 
Biotin RNA Labeling Mix (Roche). siLentfect Lipid Reagent (Bio-Rad) was 
used for transfection of siRNA (NLRX1 5 -AUCCCGACGGAAGAUGUGC-3  
and control #2, both from Dharmacon; NFKB1 from Santa Cruz). Fugen HD 
Reagent (Promega) was used for DNA transfections.
Lentivirus production and transduction. For sgRNA CRISPR-Cas9 len-
tivirus production, individual sgRNA expressing vectors and the 3rd 
Generation Packaging Mix vectors (ABM) were co-transfected into 293FT 
cells. Transduction was facilitated by the addition of 8 g/ml polybrene, and 
the resulting cells were subjected to selection with puromycin (6 g/ml) for 
single-deletion cells, and puromycin (6 g/ml) and blasticidin (10 g/ml) for 
double-deletion cells.
RNA extraction and quantitative RT-PCR. Total RNA extraction was car-
ried out with the RNeasy Kit (Qiagen), followed by two-step quantitative 
RT-PCR analysis of genes with the SuperScript III First-Strand Synthesis 
System (Invitrogen) and iTaq SYBR Green Supermix (Bio-Rad). The abun-
dance of indicated genes was normalized to that of ACTB (human) or Actb 
(mouse). The abundance of HAV and HCV RNA was quantified as previously 
described51,60.
Nuclear protein extraction. Extraction of nuclear proteins was carried out as 
previously described61, with minor modification. In brief, the washed nuclei 
pellet was re-suspended in 50 l of nuclear protein extraction buffer (20 mM 
Tris-HCl, pH 7.5, 400 mM NaCl, 1.5 mM MgCl2 and 0.2 mM EDTA) supple-
mented with complete protease inhibitor and PhoSTOP (Roche).
Protein–protein–RNA interaction. Cell lysates were prepared from 10-cm 
dish cultures (1.5 × 106 to 2 × 106 cells) with lysis buffer (20 mM Tris-HCl, 
pH 7.5, 50 mM KCl, 250 mM NaCl, 10% glycerol, 5 mM EDTA, 1× complete 
protease inhibitor and 1× PhoSTOP) supplemented with detergents as fol-
lows. For protein–protein interaction assays, 0.2% Triton X-100 and 0.3% 
NP-40 were added. The resulting lysates were used for immunoprecipitation 
as previously described62. For protein–RNA interaction, 0.5% Triton X-100 
with 0.1% NP-40 was added. Recombinant NLRX1 was generated as previ-
ously described63. Lysates were mixed with an equal volume of 2× incubation 
buffer (300 mM KCl, 40 mM HEPES, pH 7.5, 10% glycerol, 200 Units/ml 
RNaseOUT (Thermo Fisher), 10 mM magnesium acetate and 2 mM DTT). 
For precipitation, 500 ng biotin-labeled HAV RNA, 100 ng biotin-labeled 
poly(I:C) (InvivoGen) or 1 l polyclonal anti-NLRX1 was used in each reac-
tion. All reactions were gently rotated at 4 °C for 2 h, followed by the addition 
of magnetic streptavidin T1 beads (Invitrogen) for another 30 min of rotation 
or protein G-Sepharose (GE Healthcare) for another 1 h of rotation. After five 
intense washes with 1× incubation buffer, the final product was analyzed by 
qRT-PCR and/or immunoblot.
Electrophoretic mobility-shift assay, native PAGE, immunoblot analysis 
and visualization. For electrophoretic mobility-shift assays, IRDye 700-
labeled oligonucleotides containing a consensus NF- B-binding site (5 - 
AGTTGAGGGGACTTTCCCAGGC-3 ; LI-COR Biosciences) were incubated 
with nuclear extracts according to the manufacturer’s protocol (Odyssey 
Infrared EMSA kit). Electrophoresis of the resultant products was carried 
out with a 5% TBE gel (Bio-Rad). Native PAGE for analysis of IRF3 dimeri-
zation was performed as previously described64. Immunoblot analysiswas 
carried out using standard methods. An Odyssey Imaging System (Li-COR 
Biosciences) was used for visualization and signal (infrared fluorescence) 
intensity analysis.
Polysome profiling, [35S]-metabolic labeling, and puromycin incorpora-
tion assay. Control PH5CH8 cells and PH5CH8 cells depleted of NLRX1  
(2 × 107) were infected with SeV (3 × 104 HA units) for 2 h. Cells were then 
harvested, and polysome gradients were prepared and analyzed as previously 
described65. For metabolic labeling, 3 × 105 cells were infected with SeV (1.5 
× 103 HA units) for 2 h and 15 min. After 15 min of starvation in methionine- 
and cysteine-free medium, newly synthesized proteins were pulse-labeled 
with [35S]-labeled methionine and cysteine, 125 Ci [35S]/ml, for 30 min as 
described66. Protein synthesis was assessed in cells infected by SeV under simi-
lar conditions by monitoring of the incorporation of puromycin into nascent 
protein using a method described previously67. In brief, cells grown on glass 
slides were pulsed with puromycin (10 g/ml) for 10 min, then were fixed with 
4% paraformaldehyde, followed by staining with anti-puromycin and DAPI. 
Slides were imaged by laser-scanning confocal microscopy at a fixed gain in an 
Olympus FV1000 instrument at 40× magnification, and recorded images were 
analyzed with ImageJ (Fiji). Individual cells were identified by DAPI staining 
of nuclei, and were assigned scores for the intensity of the puromycin signal 
greater than an arbitrary threshold set with mock-infected control cells in each 
experiment. Alternatively, cells were lysed, and puromycin-labeled proteins 
were identified by immunoblot analysis and quantified by assessing infrared 
fluorescence intensity with the Odyssey Imaging System.
Luciferase reporter assay. Luciferase assays, including secreted Gaussia luci-
ferase (GLuc) analysis of HCV replication and dual luciferase assays to analyze 
promoter activation, were carried out as described previously57,68.
ELISA. IL-6 concentrations were determined with the human IL-6 ELISA Kit 
(eBioscience) according to the manufacturer’s protocol.
Statistical analysis. Unless noted otherwise, all between-group compari-
sons were carried out by one-way or two-way ANOVA or two-sided t-test. 
Calculations were made using Prism 6.0 software (GraphPad Software).
A Life Sciences Reporting Summary for this paper is available. Detailed 
information about experimental design and reagents used in this study can 
be found in that summary.
Data availability. Data that support the findings of this study are shown 
directly in figures accompanying the main text or in supplementary figures 
or are available from the corresponding author upon request.
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